PL3397273T3 - Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego - Google Patents

Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego

Info

Publication number
PL3397273T3
PL3397273T3 PL16826898T PL16826898T PL3397273T3 PL 3397273 T3 PL3397273 T3 PL 3397273T3 PL 16826898 T PL16826898 T PL 16826898T PL 16826898 T PL16826898 T PL 16826898T PL 3397273 T3 PL3397273 T3 PL 3397273T3
Authority
PL
Poland
Prior art keywords
glucosidase
treatment
pompe disease
fortified acid
fortified
Prior art date
Application number
PL16826898T
Other languages
English (en)
Inventor
Hung V. Do
Richie Khanna
Russell GOTSCHALL
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Priority claimed from PCT/US2016/069243 external-priority patent/WO2017117407A1/en
Publication of PL3397273T3 publication Critical patent/PL3397273T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL16826898T 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego PL3397273T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08
EP16826898.5A EP3397273B1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease
PCT/US2016/069243 WO2017117407A1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease

Publications (1)

Publication Number Publication Date
PL3397273T3 true PL3397273T3 (pl) 2021-12-06

Family

ID=60186557

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21174249.9T PL3957320T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego
PL16826898T PL3397273T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21174249.9T PL3957320T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego

Country Status (16)

Country Link
EP (4) EP3957320B1 (pl)
CN (1) CN108472340A (pl)
CY (1) CY1124637T1 (pl)
DK (3) DK4285902T3 (pl)
ES (2) ES2965190T3 (pl)
FI (2) FI4285902T3 (pl)
HK (1) HK1253014A1 (pl)
HR (3) HRP20210894T1 (pl)
HU (2) HUE064049T2 (pl)
LT (3) LT3957320T (pl)
PL (2) PL3957320T3 (pl)
PT (3) PT3397273T (pl)
RS (2) RS62212B1 (pl)
SI (2) SI3957320T1 (pl)
SM (3) SMT202600054T1 (pl)
TW (3) TW202506173A (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
HUE033381T2 (en) 2003-01-31 2017-11-28 Mount Sinai School Of Medicine Of New York Univ Combination therapy for the treatment of protein deficiency disorders
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
EP1896083B1 (en) 2005-05-17 2016-03-02 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
PL2252313T3 (pl) 2008-02-12 2015-09-30 Amicus Therapeutics Inc Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi
US20110070643A1 (en) * 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
SMT202100136T1 (it) 2012-05-03 2021-05-07 Amicus Therapeutics Inc Regimi posologici per il trattamento della malattia di pompe
CA2917995C (en) 2012-07-17 2021-01-26 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
PE20170906A1 (es) * 2014-09-30 2017-07-12 Amicus Therapeutics Inc Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados

Also Published As

Publication number Publication date
EP3957320A1 (en) 2022-02-23
TWI849380B (zh) 2024-07-21
EP3957320B1 (en) 2023-08-23
EP4706779A2 (en) 2026-03-11
SI3397273T1 (sl) 2021-11-30
FI4285902T3 (fi) 2026-02-17
DK3957320T3 (da) 2023-11-27
SMT202300412T1 (it) 2024-01-10
FI3957320T3 (fi) 2023-11-23
EP3397273A1 (en) 2018-11-07
TW202506173A (zh) 2025-02-16
CN108472340A (zh) 2018-08-31
PT4285902T (pt) 2026-02-10
PT3397273T (pt) 2021-08-09
HRP20260120T1 (hr) 2026-03-13
DK3397273T3 (da) 2021-08-09
DK4285902T3 (da) 2026-02-16
TW202245831A (zh) 2022-12-01
DK3957320T5 (da) 2024-08-05
EP3397273B1 (en) 2021-05-19
SMT202600054T1 (it) 2026-03-09
EP4285902B1 (en) 2025-11-19
HK1253014A1 (zh) 2019-06-06
EP4285902A2 (en) 2023-12-06
SI3957320T1 (sl) 2024-01-31
HRP20210894T1 (hr) 2021-07-23
LT3957320T (lt) 2023-12-11
PL3957320T3 (pl) 2024-02-19
ES2965190T3 (es) 2024-04-11
SMT202100452T1 (it) 2021-09-14
TW201726163A (zh) 2017-08-01
HUE064049T2 (hu) 2024-02-28
LT3397273T (lt) 2021-06-25
LT4285902T (lt) 2026-02-25
HUE054733T2 (hu) 2021-09-28
ES2883844T3 (es) 2021-12-09
EP4285902A3 (en) 2024-02-21
CY1124637T1 (el) 2022-07-22
PT3957320T (pt) 2023-11-23
RS62212B1 (sr) 2021-09-30
HRP20231465T1 (hr) 2024-03-01
RS64843B1 (sr) 2023-12-29
TWI753874B (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
IL283837A (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
HUE053115T2 (hu) Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
IL262211A (en) Gene therapy for treating mucopolysaccharidosis type ii
HUE059662T2 (hu) Eljárás terápiás immunsejtek hatékonyságának fokozására
HUE049323T2 (hu) Hízósejt-stabilizálók tüdõbetegség kezelésére
HRP20190165T1 (hr) Genska terapija za fabryjevu bolest
HUE059694T2 (hu) Készítmény rák kezelésére
PL3169328T3 (pl) Pochodne chinoliny do leczenia chorób zapalnych
HUE053565T2 (hu) Adagolási rendek Pompe betegség kezelésére
IL256206A (en) Mct4 inhibitors for treating disease
IL262708B (en) Di-substituted pyrazole compounds for the treatment of diseases
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
IL257764B (en) Methods for treatment of diseases
IL259297A (en) Heterocyclic compounds for the treatment of disease
HUE063820T2 (hu) Módszerek kardiovaszkuláris betegségek kezelésére
BR112016015712A2 (pt) método de tratamento de doenças hepáticas.
IL259561B (en) Methods of predicting progression of barrett's esophagus
IL259381B (en) Mirabegron for the treatment of retinal diseases
KR101583452B9 (ko) 위장질환 치료용 의약 조성물
PL3397273T3 (pl) Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego